The march toward rational therapeutics in children.
Although children suffer from many of the same diseases as adults, the majority of drugs are not approved for pediatric use. This places children at risk, either that they will not be treated adequately because of the lack of approved agents or that their physician will be lacking the necessary labeling information to treat appropriately with a given agent. This paper details the slow progress over the last 25 years toward providing pediatric labeling and thus providing children with optimal protection and range of treatment options.
Gorman
Richard L
RL
Department of Pediatrics, Univeristy of Maryland Medical School, Baltimore, USA. rgorman137@aol.com
D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D004348:Drug Labeling; D004363:Drug Utilization; D005260:Female; D006801:Humans; D007223:Infant; D007880:Legislation, Drug; D008297:Male; D020380:Needs Assessment; D010372:Pediatrics / Q000592:standards / Q000639:trends; D012680:Sensitivity and Specificity; D014481:United States; D014486:United States Food and Drug Administration